These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 19667621)

  • 1. New evidence supporting aggressive lipid lowering.
    Stein EA
    Postgrad Med; 2003 Apr; 113(4 Suppl):31-40. PubMed ID: 19667621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins and LDL-cholesterol lowering: an overview.
    Stroes E
    Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol and coronary events. The current thinking.
    Jones PH
    Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein cholesterol reduction: the end is more important than the means.
    LaRosa JC
    Am J Cardiol; 2007 Jul; 100(2):240-2. PubMed ID: 17631077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practicing effective preventive medicine. Pharmacologic interventions in coronary heart disease.
    Eisenberg DA
    Postgrad Med; 2003 Apr; 113(4 Suppl):24-30. PubMed ID: 19667620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins, super-statins and cholesterol absorption inhibitors.
    Brousseau ME
    IDrugs; 2003 May; 6(5):458-63. PubMed ID: 12789600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rising to the challenge of treating high-risk patients.
    Guthrie RM
    Am J Manag Care; 2006 Oct; 12(11 Suppl):S318-24. PubMed ID: 17042674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new "lower is better" lipid goals: are they achievable with today's drugs?
    Chilton RJ
    J Am Osteopath Assoc; 2002 May; 102(5 Suppl 1):S1-5. PubMed ID: 12046679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The patient at risk: who should we be treating?
    Leitersdorf E
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
    Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive lipid-lowering therapy: a clinical imperative.
    Pedersen TR
    Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for aggressive lipid lowering in high-risk patients.
    Cohen JD
    J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
    Brown WV
    J Am Osteopath Assoc; 2001 Sep; 101(9 Suppl):S6-11. PubMed ID: 11575043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.